# Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer

> **NCT00050141** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 121 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ZARNESTRA, tipifarnib, R115777

## Key facts

- **NCT ID:** NCT00050141
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2005-10
- **Final completion:** 2008-01
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050141, "Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00050141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*